pediatric-pathology-and-laboratory-medicine-2017

Page 65

Notes:

conferenceseries

.com

Volume 7, Issue 1 (Suppl)

J Clin Exp Pathol

ISSN: 2161-0681 JCEP, an open access journal

Pediatric Pathology & Laboratory Medicine 2017

March 15-16, 2017

March 15-16, 2017 London, UK

International Conference on

Pediatric Pathology & Laboratory Medicine

J Clin Exp Pathol 2017, 7:1 (Suppl)

Magnetic resonance spectroscopic imaging in pediatric brain tumors

A Aria Tzika

Massachusetts General Hospital - Harvard Medical School, USA

agnetic resonance (MR) techniques offer a non-invasive, non-irradiating yet sensitive approach to diagnose and monitor

pediatric brain tumors. Proton magnetic resonance spectroscopy (MRS), as an adjunct to MRI, has been more widely applied to

monitor the metabolic aspects of brain cancer.

In vivo

MRS biomarkers represent a promising method andmay influence the treatment

choice both at initial diagnosis and follow-up, given the inherent difficulties of sequential biopsies to monitor therapeutic response.

When combined with anatomical or other types of imaging, MRS provide unique information regarding biochemistry in inoperable

brain tumors and may complement neuro-pathologic data, guide biopsies and suggest therapeutic options. The combination of non-

invasively acquired prognostic information and the high-resolution anatomical imaging provided by conventional MRI is expected

to surpass molecular analysis or DNA microarray gene profiling, both of which, although promising, depend on invasive biopsy. This

presentation will focus on recent bibliographic data in the field of MRS in children with brain tumors.

Updates in lung cancer staging

R A Miller

Texas Medical Center, USA

he AJCC Cancer Staging Manual updates are scheduled to be published on or before October 31, 2016 and will be effective as of

January 1, 2017. With regard to lung cancer staging, more emphasis will be placed on tumor size in the 8th edition in order to

better stratify patient prognosis. Additional changes in the upcoming addition include factors such as diaphragm invasion, tumor

distance from the main stem bronchus, concomitant atelectasis/pneumonitis, changes in nodal status, and changes in the metastatic

category. Although therapeutic changes are not anticipated, the new addition is anticipated to place patients with newly diagnosed

lung cancer into better prognostic categories. As such, as a practicing pathologist, it is essential to have a thorough understanding of

lung cancer staging. The intent of this lecture will be to touch on the AJCC 8th edition updates and to discuss the rationale behind the

various changes. Additionally, challenges will be discussed with regard to staging patients, such as appropriately determining tumor

size, appropriate categorization of lung adenocarcinoma, and determining synchronous primaries versus metastatic lesions.